Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG Biomarkers for Pediatric ADHD Treatment Stratification
NCT07650643Phase 4Not yet recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Sep 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
A Phase 4 trial of methylphenidate hydrochloride extended-release chewable tablet, dextroamphetamine + amphetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Boston Children's Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tabletdextroamphetamine + amphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07650643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650643.